China Universal Asset Management Co. Ltd. Purchases 3,347 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

China Universal Asset Management Co. Ltd. grew its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 11.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 33,336 shares of the biopharmaceutical company’s stock after buying an additional 3,347 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Ocular Therapeutix were worth $285,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OCUL. Assenagon Asset Management S.A. purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at $24,584,000. Charles Schwab Investment Management Inc. grew its position in Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock valued at $9,661,000 after buying an additional 660,080 shares during the period. Braidwell LP increased its holdings in Ocular Therapeutix by 36.3% during the third quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company’s stock worth $19,486,000 after buying an additional 596,000 shares during the last quarter. Polar Asset Management Partners Inc. purchased a new stake in Ocular Therapeutix during the third quarter worth about $4,288,000. Finally, FMR LLC raised its position in Ocular Therapeutix by 7,098.7% in the third quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock worth $3,779,000 after acquiring an additional 428,335 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on OCUL shares. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank started coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Ocular Therapeutix Trading Down 1.0 %

Shares of OCUL stock opened at $7.70 on Monday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -5.83 and a beta of 1.23. The company’s fifty day simple moving average is $8.68 and its two-hundred day simple moving average is $9.02. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Insider Activity

In related news, insider Jeffrey S. Heier sold 2,948 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the sale, the insider now owns 269,059 shares of the company’s stock, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is owned by company insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.